CRC panel, thyroid cancer kits, 6/17
June 2017—EntroGen announced CE-IVD marking of its Colorectal Cancer Panel (CRC), Thyroid Cancer Mutation Analysis kit (THDNA), and Thyroid Cancer Fusion Gene Detection kit (THRNA).
Webinars and Sponsored Roundtables — Register Now
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace Directory
Olympus microscopes, 6/17
June 2017—The Olympus CX43 and CX33 microscopes are designed to keep users comfortable during long periods of use, maximizing work efficiency. Features of the microscopes that minimize user fatigue include a stage that is 70 mm lower than the previous model, resulting in a large working space under the eyepieces, which makes it easier to check or swap samples with just one hand; a stage knob and co-axial focus knobs that are designed lower to the microscope base so users can reach the controls while their forearms remain resting on the desk; and a low-positioned revolving nosepiece that accommodates up to five objectives and enables users to quickly change magnification with minimal arm movement.
Quest, PeaceHealth agreement, 6/17
June 2017—Quest Diagnostics and PeaceHealth have formed a two-part arrangement to enhance the delivery of laboratory services to communities in Oregon, Washington, and Alaska.
NGS cancer panels, 6/17
June 2017—Oxford Gene Technology has expanded its SureSeq myPanel NGS Custom Cancer Panel content. The expanded content covers more than 70 genes optimized for hematology and solid tumors including breast, colorectal, lung, ovarian and prostate cancer, glioma, melanoma, sarcoma, leukemias, myeloproliferative neoplasms, and myelodysplastic syndrome.
Deep learning AI analytics platform, 6/17
June 2017—Fimmic launched its next-generation WebMicroscope Deep Learning Platform. Fimmic’s cloud platform brings deep learning artificial-intelligence-based image analysis to pathologists and researchers, no matter the size of a project.
FDA-cleared next-gen troponin T test, 6/17
June 2017—Roche received 510(k) clearance for its Elecsys Troponin T Gen 5 STAT blood test for patients with a suspected heart attack. With this clearance, according to a company statement, Roche is the first IVD company in the U.S. to provide next-generation troponin testing for patients as an aid in the diagnosis of myocardial infarction, enabling clinicians to more accurately identify patients experiencing a heart attack.
Pan-ethnic solution for carrier status research, 6/17
June 2017—Thermo Fisher Scientific released its CarrierScan Assay, a high-throughput, microarray-based assay that provides molecular genetics laboratories with a consolidated and automated single pan-ethnic solution for expanded carrier status research.
Multiplexed analysis to detect gene fusions, 5/17
May 2017—Agena Bioscience announced a comparative study published in Scientific Reports highlighting the use of its mass-spec-based platform for transcriptome analysis of ALK, ROS1, and RET gene fusions in lung cancer.
Monoclonal antibodies to Shigella, 5/17
May 2017—ViroStat released two sets of monoclonal antibodies to Shigella—one set specific to Shigella sonnei and another set specific to Shigella flexneri 2a. Potential applications for these include direct bacterial detection by ELISA and lateral flow rapid tests.
Molecular flu tests cleared, 5/17
May 2017—Cepheid received FDA clearance to market Xpert Xpress Flu and Xpert Xpress Flu/RSV. Both tests deliver reference-quality molecular results in as little as 20 minutes. The tests are Cepheid’s first Xpress branded products, which are expected to deliver results in 30 minutes or less.